# Patient-One Research Outputs

**Generated:** December 29, 2025
**Patient:** PAT001-OVC-2025 (Jane TestPatient)
**Diagnosis:** Stage IV High-Grade Serous Ovarian Carcinoma (HGSOC), Platinum-Resistant

## Overview

This directory contains comprehensive spatial transcriptomics analysis outputs for Patient-001, generated using the automated patient report generator. These results are intended for **research purposes only** and demonstrate the capabilities of the precision medicine spatial analysis pipeline.

## Contents

### patient-001/

Complete analysis outputs for Patient-001, including:

#### Data Files (CSV/JSON/TXT)

1. **differential_expression.csv** (3.4 KB)
   - Differential expression analysis results
   - Tumor core vs stroma comparison
   - 31 genes analyzed, 17 significant DEGs identified
   - Columns: gene, mean_tumor, mean_stroma, log2_fold_change, p_value, fdr

2. **spatial_autocorrelation.csv** (1.5 KB)
   - Moran's I spatial statistics for all genes
   - 31 genes analyzed, all spatially significant (p < 0.01)
   - Columns: gene, morans_i, z_score, p_value

3. **cell_deconvolution.csv** (566 B)
   - Cell type signature scores by tissue region
   - 4 cell types × 6 tissue regions
   - Cell types: fibroblasts, immune_cells, hypoxic, resistant

4. **clinical_summary.txt** (2.9 KB)
   - Human-readable clinical analysis report
   - Molecular findings, spatial organization, tumor microenvironment
   - Treatment recommendations (research context)
   - Includes disclaimers

5. **metadata.json** (396 B)
   - Analysis metadata and configuration
   - Patient ID, analysis date, data sources
   - Dataset statistics (genes, spots, regions)
   - Analysis results summary

#### Visualizations (PNG, 300 DPI)

6. **volcano_plot.png** (158 KB)
   - Differential expression visualization
   - 17 significant DEGs highlighted
   - Top genes labeled: TP53, KRT8, ABCB1, BCL2L1, MKI67

7. **spatial_heatmap.png** (1.8 MB)
   - Spatial expression patterns for top 6 spatially variable genes
   - 2×3 panel layout
   - Genes: HIF1A, BCL2L1, CD3D, KRT8, MYC, VEGFA
   - Expression overlaid on tissue coordinates

8. **cell_composition_heatmap.png** (217 KB)
   - Cell type enrichment by tissue region
   - Heatmap visualization (4 cell types × 6 regions)
   - Annotated with signature scores

9. **spatial_autocorrelation_plot.png** (140 KB)
   - Moran's I bar chart for top 15 genes
   - Ranked by spatial clustering strength
   - HIF1A shows highest spatial autocorrelation (I=0.141)

10. **summary_figure.png** (1.0 MB)
    - Multi-panel publication-ready summary
    - 6 panels: DEGs, cell types, spatial patterns, region distribution, statistics
    - Single-page overview for presentations/publications

## Key Findings

### Molecular Profile

**Drug Resistance Markers Detected:**
- ABCB1 (MDR1): 4.29× upregulated - multidrug efflux pump
- PIK3CA: 3.11× upregulated - PI3K/AKT pathway activation
- AKT1: 3.24× upregulated - PI3K/AKT pathway activation
- MTOR: 3.17× upregulated - mTOR pathway activation

**Hypoxic Microenvironment:**
- HIF1A: Moran's I = 0.141 (strongest spatial clustering)
- CA9: Moran's I = 0.103 (carbonic anhydrase 9)
- VEGFA: Moran's I = 0.105 (angiogenesis)
- Hypoxic zones spatially defined in necrotic regions

**Proliferation Markers:**
- MKI67: 3.56× upregulated (proliferation)
- TOP2A: 3.48× upregulated (cell cycle)
- PCNA: expressed (DNA replication)

**Anti-Apoptotic:**
- BCL2L1: 3.68× upregulated
- BCL2: expressed

### Spatial Organization

**Tissue Regions (900 spots total):**
- stroma_immune: 212 spots (23.6%) - immune infiltration
- necrotic_hypoxic: 203 spots (22.6%) - hypoxic zones
- stroma: 180 spots (20.0%) - fibroblast-rich
- tumor_proliferative: 124 spots (13.8%) - actively dividing
- tumor_interface: 112 spots (12.4%) - invasion front
- tumor_core: 69 spots (7.7%) - central tumor

**Cell Type Enrichment:**
- **Stroma:** Fibroblast signature highest (748.6)
- **Stroma_immune:** Immune cell signature highest (603.3)
- **Necrotic_hypoxic:** Hypoxic signature highest (607.5)
- **Tumor_core:** Resistant signature highest (716.8)
- **Tumor_proliferative:** Resistant signature highest (728.7)

### Clinical Implications (Research Context)

**Potential Treatment Strategies:**
1. **PI3K/AKT Pathway Inhibitors**
   - Alpelisib (PI3K inhibitor)
   - Capivasertib (AKT inhibitor)
   - Everolimus (mTOR inhibitor)

2. **Hypoxia-Targeting Agents**
   - Evofosfamide (TH-302)
   - Hypoxia-activated prodrugs

3. **BCL2 Family Inhibitors**
   - Venetoclax (BCL2 inhibitor)
   - Navitoclax (BCL2/BCL-XL inhibitor)

4. **MDR Reversal Agents**
   - Combined with chemotherapy to overcome ABCB1-mediated resistance

5. **VEGF Inhibitors**
   - Bevacizumab (already receiving - continue)

## Analysis Pipeline

**Data Sources:**
- **Clinical Data:** GCP Healthcare API (FHIR)
  - Patient demographics
  - Diagnoses (Stage IV HGSOC, platinum-resistant)
  - Medications (Carboplatin, Paclitaxel, Bevacizumab)
  - Observations (BRCA1/2, CA-125)

- **Spatial Data:** Visium Spatial Transcriptomics
  - 31 curated cancer-related genes
  - 900 spots across tissue
  - Array-based coordinates

**Analysis Methods:**
1. **Differential Expression:** Mann-Whitney U test + Benjamini-Hochberg FDR correction
2. **Spatial Autocorrelation:** Moran's I with row-standardized weights (distance threshold = 1.5)
3. **Cell Type Deconvolution:** Signature-based scoring (mean expression of marker genes)

**Runtime:** ~12 seconds total

## Dataset Statistics

- **Genes:** 31 cancer-related genes
- **Spots:** 900 Visium spots
- **Regions:** 6 tissue regions
- **Significant DEGs:** 17 (FDR < 0.05, |log2FC| > 1)
- **Spatially Variable Genes:** 31 (all genes, p < 0.01)
- **Data Format:** CSV, JSON, TXT, PNG

## Reproducibility

**Generated Using:**
- Tool: `scripts/generate_patient_report.py`
- Version: December 29, 2025
- Command: `python scripts/generate_patient_report.py --patient-id patient-001 --output-dir ./results`
- Environment: Python 3.11, spatialtools virtual environment
- Dependencies: pandas, numpy, scipy, matplotlib, seaborn

**Source Code:**
- Repository: https://github.com/lynnlangit/precision-medicine-mcp
- Script: `scripts/generate_patient_report.py`
- Documentation: `docs/AUTOMATED_PATIENT_REPORTS.md`

## Disclaimers

⚠️ **IMPORTANT:**

1. **Research Use Only:** These analyses are for research and demonstration purposes only
2. **Not Clinical Grade:** NOT validated for clinical decision-making
3. **Synthetic Patient:** Patient-001 is a synthetic test case for demonstration
4. **Requires Validation:** All findings require independent validation before clinical use
5. **Consult Oncologists:** Treatment decisions must be made by qualified medical professionals

## Related Resources

**For Care Team:**
- See `../for-care-team/` for clinical summaries

**For Patient:**
- See `../for-patient/` for patient-friendly explanations

**For Developers:**
- See `../for-developer/` for technical implementation details
- Script: `scripts/generate_patient_report.py`
- Documentation: `docs/AUTOMATED_PATIENT_REPORTS.md`

## File Sizes

**Total:** ~3.4 MB

| File | Size | Type |
|------|------|------|
| differential_expression.csv | 3.4 KB | Data |
| spatial_autocorrelation.csv | 1.5 KB | Data |
| cell_deconvolution.csv | 566 B | Data |
| clinical_summary.txt | 2.9 KB | Report |
| metadata.json | 396 B | Metadata |
| volcano_plot.png | 158 KB | Visualization |
| spatial_heatmap.png | 1.8 MB | Visualization |
| cell_composition_heatmap.png | 217 KB | Visualization |
| spatial_autocorrelation_plot.png | 140 KB | Visualization |
| summary_figure.png | 1.0 MB | Visualization |

## Citation

If using these methods or results in research, please cite:

```
Precision Medicine Spatial Transcriptomics Analysis Pipeline
Generated with Claude Code
December 29, 2025
https://github.com/lynnlangit/precision-medicine-mcp
```

## Contact

For questions about the analysis pipeline or methods:
- Repository: https://github.com/lynnlangit/precision-medicine-mcp
- Documentation: See `AUTOMATED_PATIENT_REPORTS.md`

---

**Generated:** 2025-12-29
**Patient ID:** patient-001 (PAT001-OVC-2025)
**Analysis Type:** Spatial Transcriptomics - Complete Phase 2 Workflow
